Dr. Ed Engleman: Vivo Capital’s Cancer Hacker
Dr. Ed Engleman of Vivo Capital makes a bold prediction that most cancers will be manageable or curable within twenty years, driven by an accelerating pace of medical discovery. The conversation explores how regulatory frameworks like orphan drug designations are shaping cancer treatment development and investment strategies in biotech.
Key takeaways
- •Cancer treatment breakthroughs are accelerating at an unprecedented pace, with most cancers expected to become manageable or curable within two decades.
- •Orphan drug designations for rare diseases create unique regulatory and commercial opportunities in cancer drug development.
- •The intersection of increasing discovery speed and targeted regulatory pathways is fundamentally reshaping cancer treatment timelines.
Listen to full episode
0:00
Best moment
2 clips
Ordered by timestamp. Jump to the moment you care about.
From the blog
Want clips like this for your podcast?
We find your top 5-8 clips, write the hooks, and deliver ready-to-post content. First 2 episodes are free.
Get 2 Episodes Clipped Free